Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Hanada Website

Ken-ichi Hanada, M.D., Ph.D.

Selected Publications

1)  Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA.
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors.
J. Clin. Invest. [Epub ahead of print], 2014.
2)  Hanada K, Restifo NP.
Double or nothing on cancer immunotherapy.
Nat. Biotechnol. 31: 33-4, 2013.
3)  Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA.
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes.
Blood. 122: 1399-410, 2013.
4)  Tikhonova AN, Van Laethem F, Hanada K, Lu J, Pobezinsky LA, Hong C, Guinter TI, Jeurling SK, Bernhardt G, Park JH, Yang JC, Sun PD, Singer A.
aß T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities.
Immunity. 36: 79-91, 2012.
5)  Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC.
Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.
Cancer Res. 72: 6119-29, 2012.
6)  Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ.
An antigenic peptide produced by reverse splicing and double asparagine deamidation.
Proc. Natl. Acad. Sci. U.S.A. 108: E323-31, 2011.
7)  Wang QJ, Hanada K, Feldman SA, Zhao Y, Inozume T, Yang JC.
Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.
J. Immunol. Methods. 366: 43-51, 2011.
8)  Hanada K, Wang QJ, Inozume T, Yang JC.
Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.
Blood. 117: 4816-25, 2011.
9)  Frankel TL, Burns W, Riley J, Morgan RA, Davis JL, Hanada K, Quezado M, Rosenberg SA, Royal RE.
Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines.
Cancer Immunol. Immunother. 59: 1757-69, 2010.
10)  Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC.
Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.
J. Immunother. 33: 956-64, 2010.
11)  Inozume T, Hanada K, Wang QJ, Yang JC.
IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells.
J. Immunother. 32: 109-17, 2009.
12)  Wang QJ, Hanada K, Yang JC.
Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas.
J. Immunol. 181: 3769-76, 2008.
13)  Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP, Hanada K, Mena O, Kurlander R, Abdul T, Srinivasan R, Lundqvist A, Malinzak E, Geller N, Lerman MI, Childs RW.
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.
J Clin Invest. 118: 1099-109, 2008.
14)  Wang QJ, Hanada K, Perry-Lalley D, Bettinotti MP, Karpova T, Khong HT, Yang JC.
Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor.
J. Immunother. 28: 551-9, 2005.
15)  Hanada K, Yang JC.
Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing.
J. Mol. Med. 83: 420-8, 2005.
16)  Hanada K, Yewdell JW, Yang JC.
Immune recognition of a human renal cancer antigen through post-translational protein splicing.
Nature. 427: 252-6, 2004.
17)  Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA, Gattinoni L, Goldstein AL, Yang JC, Restifo NP.
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
J. Immunol. 173: 7209-16, 2004.
18)  Hanada K, Perry-Lalley DM, Ohnmacht GA, Bettinotti MP, Yang JC.
Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas.
Cancer Res. 61: 5511-6, 2001.
19)  Shibagaki N, Hanada K, Yamashita H, Shimada S, Hamada H.
Overexpression of CD82 on human T cells enhances LFA-1 / ICAM-1-mediated cell-cell adhesion: functional association between CD82 and LFA-1 in T cell activation.
Eur. J. Immunol. 29: 4081-91, 1999.
20)  Shibagaki N, Hanada K, Yamaguchi S, Yamashita H, Shimada S, Hamada H.
Functional analysis of CD82 in the early phase of T cell activation: roles in cell adhesion and signal transduction.
Eur. J. Immunol. 28: 1125-33, 1998.
21)  Hanada K, Tsunoda R, Hamada H.
GM-CSF-induced in vivo expansion of splenic dendritic cells and their strong costimulation activity.
J. Leukoc. Biol. 60: 181-90, 1996.
22)  Osawa M, Hanada K, Hamada H, Nakauchi H.
Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell.
Science. 273: 242-5, 1996.
23)  Hanada K, Song CZ, Yamamoto K, Yano K, Maeda Y, Yamaguchi K, Muramatsu M.
RNA polymerase I associated factor 53 binds to the nucleolar transcription factor UBF and functions in specific rDNA transcription.
EMBO J. 15: 2217-26, 1996.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/9/2014.